Navigation

AP & T 1 November 2017

AP&T: CONTENTS LISTING FOR THE 1st NOVEMBER 2017 ISSUE

The contents listing for the 1st November 2017 issue of Alimentary Pharmacology & Therapeutics is listed below and, as a member of the New Zealand Society of Gastroenterology, you have free access to all these articles when you log-in via the Members’ Area of the NZSG website - www.nzsg.org.nz

Yours sincerely

Roy

Professor R E Pounder
Co-Editor
Alimentary Pharmacology & Therapeutics
website: www.APandT.org
Follow AP&T on Twitter: @APandT

------------------------------------------------------------------------------------------------------

CONTENTS LIST FOR 1st NOVEMBER 2017 ISSUE OF
ALIMENTARY PHARMACOLOGY & THERAPEUTICS


SYSTEMATIC REVIEWS WITH META-ANALYSES

Systematic review with meta-analysis: the global recurrence rate of Helicobacter pylori (pages 773–779)
Y. Hu, J.-H. Wan, X.-Y. Li, Y. Zhu, D. Y. Graham and N.-H. Lu

Systematic review with meta-analysis: breastfeeding and the risk of Crohn's disease and ulcerative colitis (pages 780–789)
L. Xu, P. Lochhead, Y. Ko, B. Claggett, R. W. Leong and A. N. Ananthakrishnan

Systematic review with meta-analysis: the association between hepatitis E seroprevalence and haemodialysis (pages 790–799)
S. Haffar, F. Bazerbachi, M. D. Leise, J. J. Dillon, R. C. Albright, M. H. Murad, P. S. Kamath and K. D. Watt


REVIEW ARTICLES

Review article: the human intestinal virome in health and disease (pages 800–815)
S. R. Carding, N. Davis and L. Hoyles

Review article: the diagnostic approach and current management of chylous ascites (pages 816–824)
B. Lizaola, A. Bonder, H. D. Trivedi, E. B. Tapper and A. Cardenas

Review article: the role of the microcirculation in liver cirrhosis (pages 825–835)
T. Davies, S. Wythe, J. O'Beirne, D. Martin and E. Gilbert-Kawai


ELIMINATION DIETS FOR EOSINOPHILIC OESOPHAGITIS

Food elimination diets are effective for long-term treatment of adults with eosinophilic oesophagitis (pages 836–844)
C. C. Reed, C. Fan, N. T. Koutlas, N. J. Shaheen and E. S. Dellon


RIFAXIMIN FOR CIRRHOTIC COMPLICATIONS AND SURVIVAL

Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy(pages 845–855)
S. H. Kang, Y. B. Lee, J.-H. Lee, J. Y. Nam, Y. Chang, H. Cho, J.-J. Yoo, Y. Y. Cho, E. J. Cho, S. J. Yu, M. Y. Kim, Y. J. Kim, S. K. Baik and J.-H. Yoon


NAFLD-RELATED HEPATOCELLULAR CARCINOMA

Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period (pages 856–863)
R. Pais, L. Fartoux, C. Goumard, O. Scatton, D. Wendum, O. Rosmorduc and V. Ratziu


PREDICTING SVR IN HCV TREATMENT

Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C–infected patients treated with direct-acting antivirals(pages 864–872)
M. van Tilborg, F. I. Lieveld, E. J. Smolders, K. J. van Erpecum, C. T. M. M. de Kanter, R. Maan, M. van der Valk, J. E. Arends, A. S. M. Dofferhoff, H. Blokzijl, M. Bijmolen, J. P. H. Drenth, R. J. de Knegt, D. M. Burger and on behalf of the HepNed Study Group


PERSONALISED ADALIMUMAB PHARMACOKINETICS

Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial (pages 873–882)
H. Nakase, S. Motoya, T. Matsumoto, K. Watanabe, T. Hisamatsu, N. Yoshimura, T. Ishida, S. Kato, T. Nakagawa, M. Esaki, M. Nagahori, T. Matsui, Y. Naito, T. Kanai, Y. Suzuki, M. Nojima, M. Watanabe, T. Hibi and DIAMOND study group


BODY COMPOSITION PREDICTS ANTI-TNF RESPONSE

The body composition profile is associated with response to anti-TNF therapy in Crohn's disease and may offer an alternative dosing paradigm (pages 883–891)
N. S. Ding, G. Malietzis, P. F. C. Lung, L. Penez, W. M. Yip, S. Gabe, J. T. Jenkins and A. Hart


INVITED EDITORIALS

Editorial: the role of statins in the treatment of alcohol-related cirrhosis (pages 892–893)
N. Hansi and M. J. Williams

Editorial: the role of statins in the treatment of alcohol-related cirrhosis – Authors’ reply (pages 893–894)
U. C. Bang, T. Benfield and F. Bendtsen

Editorial: a novel approach to monitor mucosal healing in coeliac disease—as simple as shifting goalposts? (pages 894–895)
J. A. Tye-Din

Editorial: a novel approach to monitor mucosal healing in coeliac disease—as simple as shifting goalposts? Authors’ reply (pages 895–896)
H. Fang and J. A. Murray

Editorial: do thiopurines and biologics decrease the risk of colectomy? (pages 896–897)
K. H Allin and T. Jess

Editorial: do thiopurines and biologics decrease the risk of colectomy? Authors’ reply (pages 897–898)
C. Eriksson, Y. Cao, S. Rundquist, Y. Zhulina, I. Henriksson, S. Montgomery and J. Halfvarson

Editorial: optimising non-invasive screening for advanced liver fibrosis in NAFLD(pages 899–900)
R. S. Khan and P. N. Newsome


LETTERS TO THE EDITORS

Letter: the outcome of ulcerative colitis patients undergoing pouch surgery may be determined by pre-surgical factors (pages 901–902)
E. Ayubi and S. Safiri

Letter: the outcome of ulcerative colitis patients undergoing pouch surgery may be determined by pre-surgical factors. Authors’ reply (pages 902–903)
H. Yanai, S. Ben-Shachar, L. Mlynarsky, L. Godny, M. Leshno, H. Tulchinsky and I. Dotan

Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients (pages 903–905)
G. Fiorino, C. Correale, S. Radice, M. Allocca, F. Furfaro, D. Gilardi, D. Nagore, L. Del Rio, J. Pascual, A. Martínez and S. Danese

Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients—authors’ reply (pages 905–906)
Y. Komaki, A. Yamada, F. Komaki and A. Sakuraba

Letter: older age and male gender increase the risk of hepatocellular carcinoma after hepatitis B surface antigen (HBsAg) seroclearance (pages 906–908)
X.-Y. Zhang, R.-R. Jia, X. Xiang, W.-F. Gong, B.-D. Xiang, J.-H. Zhong and L.-Q. Li

Letter: low rates of HBV serology testing in patients with chronic hepatitis C receiving direct acting antivirals (pages 908–909)
J. Dimitroglou, D. Zampetas, L. Vasilieva, E. Koullias, I. Ketikoglou, A. Alexopoulou and S. P. Dourakis

Letter: low rates of HBV serology testing in patients with chronic hepatitis C receiving direct acting antivirals – Authors’ reply (pages 909–910)
M. M. Mücke, V. T. Mücke and J. Vermehren